So interesting that two small molecules with some structural similarities present different survival outcomes. I haven't been following every single clinical study, but from your report it seems that the survival has been compared between one of these inhibitors vs. chemotherapy alone. Has any of the studies been done with Tarceva vs Iressa in parallel?

Typical cautious statement of a pure academic scientist, although I see that Ciba Geigy Switzerland was involved in this case. Many of these suggestions appear in the conclusions of many academic papers coming from good labs from all around the world. I wonder if there aren't many diamonds in the rough that have not been picked up by the industry and transformed into a solution for human health. Some academic papers may appear on topics that are not "hot" or "current" at the time and I guess that their findings could pass by, unnoticed. Is industry screening all the literature or does it depend on the academics to have an entreprenurial and/or healing-oriented vision and connect with the industrial world to get their interest?